The JP Morgan Healthcare Conference is where the healthcare industry’s year takes shape.
Held from 12th to 16th Jan 2026, the conference drew more than 8,000 investors, CEOs, founders, and policymakers into one unusually dense ecosystem of capital and conviction.
The mood this year was neither euphoric nor defensive. It was measured, confident, and distinctly more grown-up. Deals returned early in the year, and conversations moved quickly from possibility to execution.
We saw healthcare ready to move again, but only with discipline.
The evolution of intelligent healthcare
With ChatGPT Health launched a few days before the conference, and Claude for healthcare launched during the conference, AI became the hottest topic of discussion.
In a featured discussion, J.P. Morgan’s Nick Richitt and Smarter DX co-founder Michael Gao mapped the shift to a new era of “intelligent healthcare.” Where AI moves beyond being a productive tool to actively supporting decisions, operations and strategy.
Their dialogue focused on three key transformations:
- Smarter decisions: AI is advancing from simple data sorting to actively aiding complex clinical reasoning.
- Leaner operations: It is streamlining everything from patient records to hospital workflows, freeing clinicians from administrative drag.
- Responsible growth: The critical need for “collaboration and control” to scale AI ethically and safely.
As Nick Richitt emphasised, the ultimate goal is human-centric:
“We’re moving towards a model where AI amplifies human experience.”
Strategic financial planning in a volatile climate
For emerging healthcare companies, the conference offered a clear survival guide for a volatile market. J.P. Morgan’s James Mitford and Juha Anjala, who co-head EMEA Healthcare Investment Banking, stressed that “visionary and data-driven leadership” is now non-negotiable.
Their capital playbook was pragmatic and precise:
- Guard your cash: Scrutinise burn rates and preserve financial flexibility above all else.
- Seek opportunity: Look past the noise. Recent biotech deals have sparked optimism, while medtech and healthtech are building momentum after a fresh wave of IPOs.
- Spend with precision: For commercial-stage players, they said growth still matters, but only when every dollar spent can be defended with data.
Capital discipline will replace growth at all costs.
Key event insights: what the sentiment shift means for healthtech
To cut through the volume of commentary, we synthesised insights from David Gluckman (Lazard), Freshfields, PharmaBoardroom, and Lincoln International. Together, they paint a clear picture of a market moving from speculation to strategy.
PharmaBoardroom identified this as “disciplines re-acceleration”. For healthtech and medtech stakeholders, the market is ready to move, but the bar for “quality” has shifted.
1. Human-centric AI becomes a defensive moat
Leaders reassessed the pure risk of software. Lincoln International noted that private equity and strategic buyers are cautious towards investing in standalone SaaS models as they can quickly be replicated or undercut by advancing LLMs.
They signalled that capital will flow towards tech-enabled services where AI is embedded within relationship-driven human expertise.
Startups that offer “AI + Human Expertise” (such as high-touch clinical services) will be more resilient and investible than software alone.
2. Longevity as the new “value-based care”
Another notable sentiment shift was longevity emerging as a strategic anchor and quietly replacing value-based care as the industry’s north star.
Preventive medicine is advancing faster than the business models supporting it. Investors now see opportunity in platforms that translate longevity science into scalable offerings, particularly in employer health, concierge medicine, and proactive care models.
The money is following strategies that promise long-term engagement rather than episodic treatment.
3. GLP-1s evolve into an infrastructure opportunity
David Gluckman (Lazard) and Freshfields both pointed to the continued dominance of GLP-1s, but with a more mature lens.
The focus has shifted away from the drugs themselves and toward the ecosystem required to support them at scale. This includes digital monitoring, supply chain resilience, and side-effect management. “GLP-1 companion apps” are evolving into full-scale metabolic health platforms.
Investors are looking to back the infrastructure that makes long-term outcomes and revenue sustainable.
4. Disciplined re-acceleration opens the middle of the market
PharmaBoardroom characterised the conference as one of “disciplined re-acceleration.” Unlike previous years, where only “perfect” (Grade A) or “distressed” (Grade D/F) assets traded, Lincoln International observed that “middling” assets are starting to move again.
Valuation expectations are normalising, and the market is becoming less binary. For mid-tier healthtech firms that were stuck in the valuation gap of 2024–2025, this signals a healthier M&A environment and renewed strategic optionality.
5. Open ecosystems gain ground over walled gardens
Freshfields’ legal and strategic analysis emphasised on how companies scale AI.
Proprietary, black-box AI models are facing increased resistance from large health systems concerned about transparency, compliance, and risk.
The prevailing sentiment favours “collaboration with control”. Open, interoperable ecosystems that allow oversight and auditability. For healthtech builders, this indicates that interoperability is a prerequisite for enterprise trust.
6. Europe and China reshape competitive pressure
While the U.S. remains the epicentre of healthcare capital, JPM 2026 reflected a broader global recalibration.
Europe is capable of scaling healthtech innovation, as it has talent and cost advantages. But it needs to solve its capital access issues. Meanwhile, China’s operational efficiency is being used as a benchmark rather than a threat narrative.
The “Pan-European” approach and the competition from China-based digital health models will force Western founders to prioritise operational efficiency over “growth at all costs.”
7. Fundraising becomes more granular and strategic
Finally, Lincoln International noted a structural change in how capital is being deployed. Large funds are now carving out dedicated “sleeves” for smaller check sizes, enabling them to engage earlier without overcommitting.
This evolution will benefit early-stage healthtech companies with airtight, data-backed strategies. Capital is available, but patience for vague roadmaps is not.
Final words
Perhaps the most defining sentiment from JPM 2026 is that the challenges facing healthcare leaders are now remarkably consistent across geographies.
Whether in London, Shanghai, or New York, leaders are grappling with the same questions—how to access capital, how to scale AI responsibly, and how to grow without losing trust.
The conference showed healthcare entering the age of amplification.
As global uncertainty persists, the path forward will be built on data, disciplined strategy, and innovation that always keeps the human element at its core.
-By Alkama Sohail and the AHT Team
Stay ahead of where healthcare innovation is unfolding next. Global conferences, startup showcases, and industry-defining events.
Sign up for the All Health Tech event calendar. We track the conversations that matter, so you don’t miss what’s shaping healthtech next.
